Scholar Rock Resubmits Apitegromab Marketing Authorisation Application to EMA for SMA
FROM THE WIRE · FINANCE.YAHOO.COM
Apitegromab MAA resubmission includes alternate fill-finish facility in place of Catalent Indiana LLC (part of Novo Nordisk), in alignment with guidance from EMA Alternate fill-finish facility in MAA is the same site that supported September 11, 2026 U.S. FDA approval of…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishResubmission with alternate facility; positive progress but still under regulatory review.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Scholar Rock resubmitted apitegromab MAA to EMA with alternate fill-finish facility.
- 02Alternate facility is same site that supported September 11, 2026 U.S. FDA approval.
- 03Company anticipates CHMP opinion in H1 2027.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets